We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Temperature-Controlled Catheter Ablation for Paroxysmal Atrial Fibrillation: The QDOT-MICRO Workflow Study.
- Authors
De Potter, Tom; Grimaldi, Massimo; Jensen, Henrik Kjaerulf; Kautzner, Josef; Neuzil, Petr; Vijgen, Johan; Natale, Andrea; Kristiansen, Steen Buus; Lukac, Peter; Peichl, Petr; Reddy, Vivek Y.
- Abstract
Background: A novel QDOT MICRO (Biosense Webster, Inc., Irvine, CA) catheter with optimized temperature control and microelectrodes was designed to incorporate real-time temperature sensing with contact force detection and microelectrodes to streamline ablation workflow. The QDOT-MICRO feasibility study evaluated the workflow, performance, and safety of temperature-controlled catheter ablation in patients with symptomatic paroxysmal atrial fibrillation with conventional ablation setting. Methods: This was a non-randomized, single-arm, first-in-human study. The primary outcome was pulmonary vein isolation (PVI), confirmed by entrance block after adenosine and/or isoproterenol challenge. Safety outcomes included incidences of early-onset primary adverse events (AEs) and serious adverse device effects (SADEs). Device performance was evaluated via physician survey. Results: All evaluated patients (n = 42) displayed 100% PVI. Two primary AEs (4.8%) were reported: 1 pericarditis and 1 vascular pseudoaneurysm. An additional SADE of localized infection was reported in 1 patient. No stroke, patient deaths, or other unanticipated AEs were reported. Average power delivered was 32.1±4.1 W, with a mean temperature of 40.8°C±1.6°C. Mean procedure (including 20-minute wait), fluoroscopy, and radiofrequency application times were 129.8, 6.7, and 34.0 minutes, respectively. On device performance, physicians reported overall satisfactory performance with the new catheter, with highest scores for satisfaction and usefulness of the temperature indicator. Conclusions: Initial clinical experience with the novel catheter showed 100% acute PVI success and acceptable safety and device performance in temperature-controlled ablation mode. There were no deaths, stroke, or unanticipated AEs. Fluoroscopy and procedural times were short and similar or better than reported for prior generation catheters.
- Subjects
IRVINE (Calif.); ATRIAL fibrillation; CATHETER ablation; PHYSICIANS; WORKFLOW; PULMONARY veins; RADIO frequency therapy
- Publication
JAFIB: Journal of Atrial Fibrillation, 2021, Vol 13, Issue 6, p1
- ISSN
1941-6911
- Publication type
Article